Assessment of compliance and therapeutic efficacy of albendazole treatment in Chinese patients with echinococcosis  

作　　者：Min Qin Guobing Yang Jun Yan Liying Wang Yu Feng Dong Wang Qian Wang Yanyan Hou Jiangshan Zhao Jiaxi Lei Zhiyi Wang Mingzhe Jiang Chenghang Yu Laurent Gavotte Roger Frutos 

机构地区：[1]National Institute of Parasitic Diseases,Chinese Center for Disease Control and Prevention(Chinese Centre for Tropical Diseases Research),NHC Key Laboratory of Parasite and Vector Biology,WHO Collaborating Centre for Tropical Diseases,National Centre for International Research On Tropical Diseases,Shanghai,China [2]Chaoyang District Center for Diseases Prevention and Control of Beijing,Beijing,China [3]Gansu Provincial Center for Disease Control and Prevention,Lanzhou,China [4]Chinese Centre for Disease Control and Prevention,Beijing,China [5]Sichuan Provincial Center for Disease Control and Prevention,Chengdu,China [6]Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention,Urumqi,China [7]Espace-Dev,UMR 228,Universitéde Montpellier,Montpellier,France [8]Centre de Cooperation International en Recherche Agronomique Pour Le Développement,UMR 17,Intertryp,Campus International de Baillarguet,Montpellier,France [9]Faculty of Medicine-Ramathibodi Hospital,Mahidol University,Bangkok,Thailand

出　　处：《Infectious Diseases of Poverty》2024年第6期109-109,共1页贫困所致传染病(英文)

基　　金：NHC Key Laboratory of Echinococcosis Prevention and Control,China(Grant No.2024WZK1001);Gansu Provincial Health Industry Research Plan Project(Grant No.GSWSKY2017-19);the Natural Science Foundation of Gansu Province,China(Grant No.21JR11RA182).

摘　　要：Background Echinococcosis is an infectious parasitic disease that is extremely harmful to human health.Albendazole is provided free of charge to patients requiring medication under the central government finance transfer payment scheme for echinococcosis control and prevention in China.Our aim is to monitor the state of patient medication and its therapeutic impact,which will help improve medication compliance and the therapeutic effect.Methods Random cluster sampling was used to select 10 echinococcosis-endemic counties in China,and all alben-dazole-treated patients in these counties were investigated.The chi-square and Kruskal-Wallis tests were used to com-pare two or more rates or constituent ratios,and multiple logistic regression analysis was used to identify the influ-encing factors.The records of patients were reviewed to obtain the initial diagnosis results as well as the most recent follow-up results and time,and efficacy was assessed.Results We examined 899 patient files treated with albendazole in 10 endemic counties.Of the 582 evaluable files,7.9%did not take albendazole,and 69.2%did not take albendazole regularly.Only 22.9%took albendazole regularly.Of the 536 patients who took albendazole,242 exhibited adverse reactions.Patients who were Tibetan,herdsmen,received no formal education,used emulsion,and exhibited adverse reactions demonstrated poor compliance.A total of 174 patients with cystic echinococcosis received their most recent imaging follow-up results within one year of the investigation date.Among them,9 patients met the criteria for cure,accounting for 5.2%;56 patients showed effectiveness,accounting for 32.2%;105 patients were deemed ineffective,accounting for 59.8%;5 patients experienced recurrence,accounting for 2.9%.Conclusions Albendazole medication compliance in patients with echinococcosis is not ideal.We must prioritize health education and promotion for Tibetans,herdsmen,and those without formal education.Patients who adhered to their medication regimen achieved higher rates of cur

关 键 词：ALBENDAZOLE THERAPY Medication compliance ECHINOCOCCOSIS Therapeutic efect 

分 类 号：R73[医药卫生—肿瘤]